Comparing NicoBloc to Nicotine Lozenges



Status:Recruiting
Conditions:Smoking Cessation, Smoking Cessation, Tobacco Consumers
Therapuetic Areas:Pulmonary / Respiratory Diseases
Healthy:No
Age Range:18 - Any
Updated:3/27/2019
Start Date:March 21, 2019
End Date:October 3, 2021
Contact:Karen L Cropsey, Psy.D.
Email:kcropsey@uabmc.edu
Phone:2059757809

Use our guide to learn which trials are right for you!

A Pilot Trial Comparing NicoBloc to Nicotine Lozenges: Initial Acceptability and Feasibility Trial

To examine the feasibility, acceptability, and preliminary impact of using NicoBloc compared
to nicotine lozenges

Smoking remains the leading cause of preventable death in the U.S. with approximately 18% of
the population continuing to smoke. However, smoking is concentrated in disadvantaged
populations where the prevalence of smoking may be as high as 70-80 %. Participants will
receive a sampling experience (use of nicotine lozenges or NicoBloc during sessions) with
counseling focused around their experience of using these interventions, including side
effects and smoking cessation expectancies.

Inclusion Criteria:

1. 18 years or older

2. planning to live in the Birmingham Metro area for the next 3 months

3. Smoking at least 5 cigarettes per day for the past year and a Carbon Monoxide>8ppm to
ensure daily smoking. This relatively low cutoff was chosen due to the expectation of
enrolling a large >50% African-American average <10 cigarettes per day compared to
Whites who average ~15 cigarettes per day

4. exclusive use of filtered cigarettes

5. English speaking.

Exclusion Criteria:

1. Living in a restricted environment that does not allow smoking (e.g., prison or jail
facility, etc.)

2. Pregnant or nursing (all women of childbearing potential will be required to use an
acceptable form of contraception)

3. Currently enrolled in a smoking cessation treatment program, using nicotine
replacement products, or prescribed bupropion or varenicline

4. Known allergy nicotine lozenge

5. Within one month post-myocardial infarction or untreated severe angina

6. Cognitive impairment or unstable psychiatric condition that interferes with the
informed consent process (individuals stable on psychiatric medications will be
included)

7. Daily or exclusive use of other tobacco products (e.g., electronic cigarettes, little
cigars, etc.).
We found this trial at
1
site
1720 2nd Ave S
Birmingham, Alabama 35233
(205) 934-4011 
Principal Investigator: Karen Cropsey, Psy.D.
Phone: 205-975-7809
University of Alabama at Birmingham The University of Alabama at Birmingham (UAB) traces its roots...
?
mi
from
Birmingham, AL
Click here to add this to my saved trials